文献速递呼吸道感染

新型肺超声方案评估COVID-19肺炎肺损伤范围的可行性

Feasibility of a New Lung Ultrasound Protocol to Determine the Extent of Lung Injury in COVID-19 Pneumonia.
PubMed 文献 · Chest · 2022-07-31

本研究纳入179例急诊确诊COVID-19肺炎患者,评估基于肺表面典型征象扩展百分比分级的肺超声方法(LUSext)的可行性及其与CT容积测量(CTvol)的相关性。结果显示LUSext可行性100%,操作时间5±1.5分钟,与CTvol正相关(R=0.67;P<.0001),两者与PaO2/FiO2比值均呈负相关(R=-0.66和R=-0.54;P<.0001)。

要点

  • LUSext在COVID-19肺炎患者中可行性达100%,操作快捷(5±1.5分钟)。
  • LUSext与CTvol正相关(R=0.67;P<.0001),可反映病变严重程度。
  • LUSext与PaO2/FiO2负相关(R=-0.66),与CTvol类似(R=-0.54)。

核心结论

  • LUSext是与CT扫描相比有效的病变严重程度测量方法。
  • LUSext与CTvol相关,且两者与呼吸衰竭严重程度呈相似负相关。
  • LUSext是CoARDS肺炎严重程度的实用简便床旁测量方法,其临床和预后影响需进一步研究。

研究设计与样本

  • 观察性研究,采用便利抽样纳入急诊确诊COVID-19且床旁LUS和CT显示肺炎的患者。
  • 共分析179例患者数据;LUSext视觉量化,CT扫描回顾性用专用软件计算CTvol。

主要发现

  • LUSext可行性为100%,操作时间5±1.5分钟。
  • LUSext与CTvol正相关(R=0.67;P<.0001)。
  • LUSext与PaO2/FiO2比值负相关(R=-0.66;P<.0001),CTvol与PaO2/FiO2比值负相关(R=-0.54;P<.0001)。

关键数值与推荐

  • LUSext基于肺表面COVID-19肺炎典型征象扩展百分比分级。
  • LUSext与CTvol相关(R=0.67;P<.0001),与PaO2/FiO2相关(R=-0.66;P<.0001)。

临床怎么用

  • LUSext可作为急诊或床旁评估COVID-19肺炎病变严重程度的简便工具。
  • LUSext与CTvol及氧合指标相关,可能辅助判断呼吸衰竭严重程度。

局限性

  • 为观察性研究,采用便利抽样。
  • LUSext的临床和预后影响尚未明确,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lung ultrasound (LUS) scanning is useful to diagnose and assess the severity of pulmonary lesions during COVID-19-related ARDS (CoARDS). A conventional LUS score is proposed to measure the loss of aeration during CoARDS. However, this score was validated during the pre-COVID-19 era in patients with ARDS in the ICU and does not consider the differences with CoARDS. An alternative LUS method is based on grading the percentage of extension of the typical signs of COVID-19 pneumonia on the lung surface (LUSext). RESEARCH QUESTION: Is LUSext feasible in patients with COVID-19 at the onset of disease, and does it correlate with the volumetric measure of severity of COVID-19 pneumonia lesions at CT scan (CTvol)? STUDY DESIGN AND METHODS: This observational study enrolled a convenience sampling of patients in the ED with confirmed COVID-19 whose condition demonstrated pneumonia at bedside LUS and CT scan. LUSext was visually quantified. All CT scan studies were analyzed retrospectively by a specifically designed software to calculate the CTvol. The correlation between LUSext and CTvol, and the correlations of each score with Pao2/Fio2 ratio were calculated. RESULTS: We analyzed data from 179 patients. Feasibility of LUSext was 100%. Time to perform LUS scan was 5 ± 1.5 mins. LUSext and CTvol were correlated positively (R = 0.67; P < .0001). Both LUSext and CTvol showed negative correlation with Pao2/Fio2 ratio (R = -0.66 and R = -0.54; P < .0001, respectively). INTERPRETATION: LUSext is a valid measure of the severity of the lesions when compared with the CT scan. Not only are LUSext and CTvol correlated, but they also have similar inverse correlation with the severity of respiratory failure. LUSext is a practical and simple bedside measure of the severity of pneumonia in CoARDS, whose clinical and prognostic impact need to be investigated further.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Volpicelli G, Fraccalini T, Cardinale L, et al. Feasibility of a New Lung Ultrasound Protocol to Determine the Extent of Lung Injury in COVID-19 Pneumonia. Chest. 2022. PMID: 35921882. doi:10.1016/j.chest.2022.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。